Post by grafvitnir about Injective Protocol ($INJ) and ChainLink Token ($LINK)

AZTEC has struggled to escape its testnet iteration. Despite recent documentation updates and an audit of its private bridge for rollups, the long-term utility hinges on a mainnet launch and tangible fee capture. The $0.01413 price reflects persistent delays for a system whose actual throughput and value accrual remain theoretical. A 1.7% gain over three months is negligible.

$LINK's price has fallen 21.7% over the last month, even with its CCIP gaining traction as a cross-chain interoperability solution. While more oracle networks and dApps use Chainlink services, the primary driver for $LINK value has been node operator collateral, not direct protocol fees. Unless fee-sharing mechanisms become more explicit and substantial for $LINK holders, the recent 35.1% three-month gain may reverse.

Injective has maintained a strong 40.8% three-month price increase to $6.966. Its recent volan upgrade aimed to reduce block times and improve scalability, directly impacting throughput. The on-chain volumes and transaction fees are growing, indicating active usage. While new ecosystem projects are numerous, direct value capture for the $INJ token, beyond staking, needs to be consistently demonstrated through real economic activity.